ProBNP for stratifying patients with heart failure;ProBNP na estratificação clínica dos pacientes com insuficiência cardíaca

Arquivos Brasileiros de Cardiologia

Volumn 81, Issue 3, 2003, Pages 239-248

  Pereira Barretto, Antonio Carlos ^a   De Oliveira Jr , Mucio Tavares ^b   Franco, Fabio Gazellato ^b   Cassaro Strunz, Célia ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

Decompensation; Heart Failure; ProBNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY;

EID: 0141926674     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0066-782X2003001100004     Document Type: Article

References (36)

1. Braunwald E, Collucci WS, Grossman W. Clinical aspects of heart failure. In: Braunwald E., ed. Heart Disease. A Textbook of Cardiovascular Medicine. 5th Edition. Philadelphia: WB Saunders Co., 1997: 445-70.
2. Stocco R, Pereira-Barretto AC. Insuficiência Cardíaca Congestiva - Critérios Diagnósticos. In: Timerman A, Cesar LAM, eds. Manual de Cardiologia -SOCESP. 1st Edition. São Paulo: Atheneu, 2000: 32-5.
3. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third sound in patients with heart failure. N Engl J Med 2001;345:574-81.
4. Remme WJ, Swedberg K. Task force report. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
5. II Diretrizes para o Diagnóstico e Tratamento da Insuficiência Cardíaca. Arq Bras Cardiol 2002; 79(suppl IV): 1-46.
6. Adams KF, Mathur VS, Georghiade M. B-type natriuretic peptide: from bench to bedside. Am Heart J 2003; 145: S34-S46.
7. Masel AS, Krishnaswam YP, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
8. Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38: 1934-41.
9. Villacorta H, Duarte A, Duarte NM, et al. Valor do peptídeo natriurético cerebral no diagnóstico de insuficiência cardíaca congestiva em pacientes atendidos com dispnéia na unidade de emergência. Arq Bras Cardiol 2002; 79: 564-72.
10. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-9.
11. Shuthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002; 87: 97-8.
12. Pereira-Barretto AC, Ramires JAF. Insuficiência cardíaca: um problema de Saúde Publica. Rev Bras Cardiol 2000; 2: 142-7.
13. Giles T. The cost-effective way forward for the management of the patient with heart failure. Cardiology 1996; 87(suppl 1): 33-9.
14. DATASUS - Ministério da Saúde - http//www.datasus.gov.Br
15. Arnold JMO, Yusuf S, Young J, et al. Prevention of heart failure in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 1284-90.
16. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385-90.
17. Starr I, Luchi RJ. Blind study on the action of digitoxin on elderly women. Am Heart J 1969; 78: 740-51.
18. Johnson GD, McDevitt DG. Is maintenance digoxin necessary in patients with sinus rhythm? Lancet 1979; 1: 567-70.
19. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539-44.
20. Packer M, Gheorguiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting-enzyme inhibitors. N Engl J Med 1993; 329: 1-7.
21. Uretsky BF, Young JB, Shahidi, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955-62.
22. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
23. Oliveira Jr MT, Pereira-Barretto AC, Canesin MF, Terzi CB, Wasjbrot DB, Ramires JAF. Mortalidade hospitalar e preditores de óbito empacientes com insuficiência cardíaca descompensada. Rev Soc Cardiol Estado de São Paulo 2000; 10: 38.
24. Canesin MF, Giorgi D, Oliveira Jr MT, et al, Ambulatory blood pressure monitoring of patients with heart failure: a new prognosis marker. Arq Bras Cardiol 2002; 78: 83-9.
25. Del Carlo CH. Pereira-Barretto AC, Cassaro-Stuntz C, Latorre RDO, Ramires JAF. Cardiac troponin T and left ventricular ejection for early risk stratification in decompensated heart failure. J Card Fail 2001; 7: 68.
26. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
27. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
28. Coats AJS. Heart failure. What causes the symptoms of heart failure? Heart 2001; 86: 574-78.
29. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
30. Mason S, Vago T, Baldi G, et al. Comparative measurement of N-terminal Pro-brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 2002; 40: 761-63.
31. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
32. Omland T, Persson A, Ng L, et al. N-terminal Pro-B type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-18.
33. Richards AM, Nicholls G, Yandle TG, et al. Plasma N-terminal Pro-brain natriuretic peptide and adrenomedullin: new neuro-hormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-9.
34. Zugck C, Haunstetter A, Kruger C, et al. Impact of beta-blocker treatment on the prognosis value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002; 39: 1615-22.
35. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.
36. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.